GRIA3 and frontotemporal dementia: Recently, the identification of autoantibodies against the GluA3 subunit of AMPAR in about 20% to 25% of patients with frontotemporal dementia (FTD) [53] opened new indications for a pathogenetic role of glutamate receptors’ autoantibodies in neurodegenerative diseases characterized by alterations of glutamatergic neurotransmission [54,55].